By Marleen Kaesebier

(Reuters) -Swiss contract drug manufacturer Lonza confirmed its full-year guidance on Thursday after a strong third quarter for its main contract development and manufacturing organization (CDMO) business.

The Basel-based company continues to expect a core earnings before interest, taxes, depreciation and amortization margin of 30% to 31% for the CDMO business in 2025. The business had made up about 86% of the company’s half-year sales.

Lonza signed large contracts in the third quarter and also expects “a healthy level of contract signings across technologies and sites” in the CDMO business for the full year, it said.

A “significant long-term commercial supply agreement” confirmed for Vacaville in the U.S. was the most material disclosure in the quarterly update, a

See Full Page